Advertisement

Programme of the EAU 3rd North Eastern European Meeting (NEEM)

        Friday, 11 September 2009

        Tabled 1
        07.30–09.00Registration
        09.00–09.10Welcome and introductionPlenary room
        W. Artibani, Padua (IT)
        A. Sikorski, Szczecin (PL)
        09.10–10.30Penile surgeryPlenary room
        09.10–09.30Update on management of penile cancer
        T. Demkow, Warsaw (PL)
        09.30–09.50Surgical correction of urethral strictures
        O. Lindell, Helsinki (FI)
        09.50–10.10The treatment of Peyronie's disease
        K. Krajka, Gdansk (PL)
        10.10–10.30Why circumcision is not mutilation
        M. Marberger, Vienna (AT)
        10.30–10.50Coffee break and poster viewing
        Tabled 1
        10.50–12.30Poster session 1: Prostate CancerRoom 1
        N1.Audit of PSA and Gleason scoring in prostatic carcinoma, J.A. Al Shakarchi*, D.Wasfi (Birmingham, Dudley, United Kingdom)
        N2.Variations in RNASEL, MSR1 and E-cadherin genes and prostate cancer in Poland, B.P. Gliniewicz*, C. Cybulski, D.Wokołorczyk, A. Sikorski, J. Lubiński (Szczecin, Poland)
        N3.Pelvic floor muscles evaluation in patients with erectile dysfunction after radical prostatectomy, T.G. Markosyan*, V. Grigoryan, S.S. Nikitin (Moscow, Russia)
        N4.Phase II study of ketoconazole combined with weekly doxorubicin in patients with hormone-refractory prostate cancer, D. Argirovic*, A. Argirovic (Belgrade, Serbia)
        N5.The use of CT in the staging of prostate cancer, M. Rohrsted*, K.J. Mikines (Copenhagen, Denmark)
        N6.BRCA2 gene mutation characterization in hereditary prostate cancer patients in Latvia, A. Abele, J. Plonis*, E. Miklasevics, E. Vjaters, A. Irmejs, J. Gardovskis, G. Trofimovics (Riga, Latvia)
        N7.Trinucleotide repeat length polymorphisms of the androgen receptor gene – a step forward in understanding the pathogenesis of prostate cancer, A. Lemiński*, A. Bińczak-Kuleta, M. Kaczmarczyk, M. Ostanek, K. Skonieczna, M. Kryształowska, B. Łoniewska, A. Ciechanowicz, M. Słojewski, A. Sikorski (Szczecin, Poland)
        N8.Clinical and histopathological characteristics of Finnish familial prostate cancers, S. Pakkanen*, M.P. Matikainen, N. Ha, P. Kujala, P.A. Koivisto, J. Schleutker, T.L.J. Tammela (Tampere, Finland)
        N9.Impact of Neoadiuvant Hormonal Therapy (NHT) on prostate cancer Gleason score and staging based on the comparison of TRUScoreBx and post radical prostatectomy specimens, P. Sikorska-Radek, M. Soczawa*, J. Smigielski, J. Matych (Lodz, Szczecin, Poland)
        N10.Volume and localization of the prostate tumor as the predictive factors of the prostate cancer stage, A.I. Urbansky* (St. Petersburg, Russia)
        N12.Preventive role of postoperatively early introduced intracavernosal PGE1 injections on the development of blood flow disturbances in penis after radical prostatectomy, P. Petrasz*, M. Słojewski, A. Lemiński, A. Gołubiński, A. Sikorski (Szczecin, Poland)
        N13.Minimal-invasive surgery – what do we mean by this? Radical perineal prostatectomy (suprasphincteric) RPP and Transperineal Lymphadenectomy (TPL) as minimal-invasive method of the treatment of prostate cancer. Technique of the procedure and own experience, S. Wronski* (Bydgoszcz, Poland)
        N14.Could the effect of therapy depend on the prostate movements during irradiation?, H.A. Urbańczyk*, L. Hawrylewicz, L. Misztal, I. Wesołowska, W. Majewski, J. Ciechowicz, L. Miszczyk, K. Ś losarek (Gliwice, Łódz, Poland)
        N15.Surgical anatomy of the prostatic urethra. A pilot ex vivo study, A. Antoniewicz*, P. Chlosta, J. Jaskulski, S. Poletajew, L. Zapala, A. Borówka (Warsaw, Poland)
        N16.Vascular disorders in cavernosal bodies limit the effectiveness of treatment of erectile dysfunction following radical prostatectomy, P. Petrasz*, M. Słojewski, A. Gołąb, A. Sikorski (Szczecin, Poland)
        N17.TMPRSS2: ERG gene fusion and epigenetic changes in tumour suppressor genes are associated with clinical markers of poor prognosis in prostate cancer patients, F. Jankevicius*, S. Jarmalaite, R. Sabaliauskaite, N. Kalinauskaite, D. Dasevicius, A. Laurinavicius, J. Lazutka (Vilnius, Lithuania)
        N18.How to improve the reconstruction of prostate MRI imaging to transrectal ultrasound imaging?, S. Bąk*, W. Lipczyński, B. Glazar, Z. Dobrowolski, A. Urbanik, R. Chrzan (Cracow, Poland)
        Tabled 1
        10.50–12.30Poster session 2: BPH and Prostate BiopsyRoom 2
        N19.Autonomic nervous system activity in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia estimated by heart rate variability, K. Juszczak*, M. Mazur, M. Wyczółkowski, P.J. Thor (Cracow, Poland)
        N20.Tamsulosin with or without serenoa repens in benign prostatic hyperplasia: The Comb TAMSR trial, D. Argirovic* (Belgrade, Serbia)
        N21.Comparative effects of rosuvastatin and simvastatin on growth of normal prostatic epithelial cells at clinically relevant concentrations, T. Murtola*, H. Syvälä, P. Pennanen, M. Bläuer, T. Ylikomi, T.L.J. Tammela (Jyväskylä, Tampere, Finland)
        N22.The diode laser: The new laser system for the transurethral vaporization of prostate – preliminary experience, M. Gałęski*, A. Sikorski (Szczecin, Poland)
        N23.Lower urinary tract symptoms and their severity in men subjected to prostate biopsy due to suspicion of prostate cancer, L. Nyk*, J. Dobruch, A. Borówka, E. Modzelewska, J. Tyloch, B. Misterek, E. Czapkowicz, E. Bres-Niewada, E. Keller (Warsaw, Bydgoszcz, Poland)
        N24.Comparison of two simple algorithms avoiding unnecessary prostate biopsy in PSA based prostate cancer detection program, R. Adomaitis*, A. Zalimas, F. Jankevicius (Vilnius, Lithuania)
        N25.Are sextant biopsies still justified?, D. Milonas*, A. Zabarskas, J. Masilunas, K. Kucinskas, S. Auskalnis, M. Jievaltas (Kaunas, Lithuania)
        N26.Repeat prostate biopsies – when and for whom?, D. Milonas, A. Grybas*, A. Zabarskas, J. Masiliunas (Kaunas, Lithuania)
        N27.Is there a need of routine pathological examination of all tissue specimens taken during benign prostate hyperplasia surgery?, M. Skrzypczyk, S. Poletajew*, J. Dobruch, A. Antoniewicz, T. Dzik, A. Borówka (Warsaw, Poland)
        N28.Reduction of PSA values after levofloxacin therapy in patients with PSA greater than 4 ng/ml: Implications for prostate cancer detection, G. Bozdogan, B. Erol*, B. Akduman, H. Tokgoz, I. Donmez, G. Mungan, N.A. Mungan (Zonguldak, Turkey)
        N29.Photoselective vaporization of the prostate with Greenlight HPS 120 W laser in patients with benign prostatic hyperplasia – results of treatment of first 100 consecutive patients, H. Zieliński, G. Piotrowicz* (Warsaw, Poland)
        N30.Green laser vaporization of the prostate – 300 procedures experience, M. Lipinski*, L.M. Jeromin, W. Różański (Todz, Lodz, Poland)
        N31.Detection rate of prostate cancer in double sextant biopsy regions, A.E. Pryalukhin*, A.I. Urbansky, M.E. Topuzov (Saint Petersburg, Russia)
        N32.Determination of free/total prostate specific antigen ratio in different age categories for diagnosis of prostate carcinoma, B. Erol*, N.A. Mungan, K. Onem, B. Akduman, G. Bozdogan, G. Mungan, H. Tokgoz, C. Eken (Zonguldak, Istanbul, Antalya, Turkey)
        Tabled 1
        10.50–12.30Poster session 3: Bladder CancerRoom 3
        N33.The rate of incidental prostate cancer in patients who underwent radical cystoprostatectomy and its clinical significance, M. Sunay*, L. Emir, S. Bagbancı, M. Dadalı, D. Erol (Ankara, Turkey)
        N34.The evaluation of recurrence rates within the first year for Ta T1 low and intermediate transitional cell carcinoma of the bladder to change the routine follow-up cystoscopies, S. Güney, S. Arısan, C. Sönmez*, E. Ergenekon (erIdot;stanbul, Turkey)
        N35.Pathophysiological and clinical problems after urinary diversion, R. Bliucukis*, S. Walter (Odense, Denmark)
        N36.Laparoscopic nephroureterectomy combined with transurethral laser excision of a rosette in urinary bladder as a modern treatment method of upper urinary tract carcinomas (Preliminary report), J. Kawecki, A. Szedel, M. Tkocz, H. Augustyniak, W. Pawlowski, M. Kupajski* (Katowice, Poland)
        N37.Macroscopic haematuria – a leading urological problem in patients on anticoagulant therapy. Is the common diagnostic standard still advisable?, A. Antoniewicz, L. Zapala*, S. Poletajew, A. Borówka (Warsaw, Poland)
        N38.How accurate we really are in predicting final stage of non-invasive TCC of the bladder when performing cystoscopy?, A. Antoniewicz, P. Chlosta, M. Skrzypczyk*, A. Borówka (Warsaw, Poland)
        N39.The evaluation of the angiotensin-converting enzyme gene polymorphism in Ta,T1 and invasive bladder cancer, N.A. Mungan, B. Erol*, G. Bozdogan, A. Dursun, S. Bozdogan, S. Baltaci, K. Onem, A. Zumrut, H. Tokgoz (Zonguldak, Ankara, Istanbul, Turkey)
        N40.Optical coherent tomography for surgery and urology using: A systematic review, S. Kharchenko*, T. Drewa, B. Sikorski (Bydgoszcz, Poland)
        N41.Expression levels of P53 and CDKN2a/ARF messenger RNA detected by Real-Time PCR in tumor tissue in bladder cancerclinicopathological applications, E.M. Borkowska*, M. Traczyk, A. Jedrzejczyk, M. Pietrusinski, B.A. Kaluzewski (Lodz, Poland)
        N42.Interesting tumor case – lymphoma of the bladder, L. Wojnar*, Z. Kwias, M. Malkowski, A. Antczak, W. Malendowicz (Poznań, Poland)
        N43.Is Carcinoma In Situ (CIS), a contra-indication for neoadjuvant chemotherapy for Transitional Cell Carcinoma (TCC) of the bladder?, M.S. Ahmad*, J. Cresswell, N.U. Eronini, J.E. Whiteway, A.C. Thorpe (Stockton on Tees, Middlesbrough, United Kingdom)
        N44.The value of combined transurethral resection and adjuvant hormonal therapy in treatment of bladder endometriosis, T. Borkowski*, B. Kuzaka, J. Michalec (Warsaw, Poland)
        N45.Laparoscopic partial nephroureterectomy in the treatment of hydronephrosis of the upper pole of duplex kidney with megaureter, P. Wiśniewski*, P. Jarzemski, S. Listopadzki, R. Kalinowski (Bydgoszcz, Poland)
        Tabled 1
        12.30–13.30Lunch
        13.30–14.50Early diagnosis of prostate cancer–risks and benefitsPlenary room
        13.30–13.50The new data
        M. Graefen, Hamburg (DE)
        13.50–14.10Biopsy technique to avoid detecting cancers not to be detected
        A. Golab, Szczecin (PL)
        14.10–14.30Evaluating the aggressive potential in the individual patient
        T. Tammela, Tampere (FI)
        14.30–14.50Biochemical failure after curative treatment
        R. Zdrojowy, Wroclaw (PL)
        14.50–15.20Coffee break and poster viewing
        Tabled 1
        15.20–17.00Poster session 4: Overactive bladder, Incontinence, Prostatitis, MiscellaneousRoom 1
        N46.Animal models of overactive bladder: Cyclophosphamide (CYP)-induced cystitis in rats, K. Juszczak*, M. Wyczółkowski, P.J. Thor (Cracow, Poland)
        N47.Urodynamic effects of the bladder C-fiber afferent activity modulation in chronic overactive bladder model rats, K. Juszczak*, M. Wyczółkowski, P.J. Thor (Cracow, Poland)
        N48.Alterations in urinary bladder histological structure and mast cells activity following overactive bladder in rats, K. Juszczak*, M. Wyczółkowski, P.J. Thor (Cracow, Poland)
        N49.Male sling operations in male urinary incontinence, M. Sunay*, L. Emir, M. Dadalı, S. Bagbancı, D. Erol (Ankara, Turkey)
        N50.Associations between lower urinary tract symptoms and semen quality in ageing male, K. Ausmees*, M. Źarkovski, G. Timberg, P. Korrovits, M. Punab (Tartu, Tallinn, Estonia)
        N51.Prevalence of asymptomatic inflammatory prostatitis in ageing male with lower urinary tract symptoms, K. Ausmees*, M. Źarkovski, G. Timberg, P. Korrovits, M. Punab (Tartu, Estonia)
        N52.Prognostic clinical markers for asymptomatic prostatitis in ageing male with lower urinary tract symptoms, K. Ausmees*, M. Źarkovski, G. Timberg, P. Korrovits, M. Punab (Tartu, Tallinn, Estonia)
        N53.The role of hyperosmolarity in micturition: Physiological model of overactive bladder, K. Juszczak*, M. Wyczółkowski, P.J. Thor (Cracow, Poland)
        N54.Does the number of prostatic epithelial progenitors depend on age?, L. Pokrywka*, M. Jasinski, A. Kaznica, P. Chlosta, T. Drewa, Z. Wolski (Bydgoszcz, Kielce, Poland)
        N55.An analysis of the main causes and evaluation of the results of a surgical treatment of vesico-vaginal fistulas, T. Gawlik-Jakubczak*, A. Klejnotowska, K. Krajka (Gdynia , Gdansk, Poland)
        N56.Is botulinum toxin type A intraprostatic injections effective in patients with urinary retention?, M. Jasinski*, T. Drewa, J. Tyloch, Z. Wolski (Bydgoszcz, Poland)
        N57.Three-dimensional ultrasonography (3D USG) administration in evaluation antibiotic distribution given intraprostatic injection during chronic prostatitis, J. Tyloch*, Z. Wolski, T. Drewa (Bydgoszcz, Poland)
        N58.Difficulties of qualification in patients to implant an artificial urethral sphincter, Z. Wolski, M. Gruszczyński*, M. Tworkiewicz (Bydgoszcz, Poland)
        N59.Improvement of nocturnal enuresis after adenotonsillectomy in children with obstructive sleep apnea syndrome, A. Gökçe*, S. Aslan, F.R. Yalçınkaya, M. Davarcı, Y.S. Kaya, N. Savas, S. Gorur, S. Dagli, A.N. Kiper, M.D. Balbay (Hatay, Turkey)
        N60.Treatment of the stress incontinence using different types of Trans Obturator Tape (TOT) in women – analysis of failures after surgery, M. Mikulska-Jovanović, Z. Wolski, A. Łapuć, L. Pokrywka* (Bydgoszcz, Poland)
        Tabled 1
        15.20–17.00Poster session 5: Renal diseaseRoom 2
        N62.Laparoscopic living donor nephrectomy – first Polish cases experience, M. Słojewski*, A. Gołąb, K. Ciechanowski, T. Sulikowski, L. Domański, M. Ostrowski, A. Sikorski (Szczecin, Poland)
        N63.Natural history of renal tumors in von Hippel-Lindau syndrome, B.P. Gliniewicz*, C. Cybulski, J. Lubiński, A. Sikorski (Szczecin, Poland)
        N64.The results of multidisciplinary treatment of metastatic renal cell carcinoma, H. Zieliński, A. Wieczorek*, A. Małczyński, J. Anusik, W. Chudzik (Warsaw, Poland)
        N65.Survival analysis for localized low-differentiated renal cell carcinoma, A. Gołubiński*, B. Gliniewicz, M. Słojewski, A. Sikorski (Szczecin, Poland)
        N66.Protective value of a folkloric medicinal plant extract against mortality and hemorrhage in acute renal trauma model in heparinized rats, H. Tokgoz, K. Karakaya, V. Hanci, M. Abdusoglu, B. Erol*, O. Turksoy, B. Akduman, N.A. Mungan (Zonguldak, Turkey)
        N67.RFA of the tumors in the solitary kidney, M. Matuszewski*, J. Michajłowski, K. Krajka (Gdańsk, Poland)
        N68.Protective effect of caffeic acid phenethyl ester on cyclosporine A-induced nephrotoxicity in rats, A. Gökçe*, S. Oktar, M. Aydın, S. İlhan, Z. Yönden, O.V. Ozkan, M. Davarcı, F.R. Yalçınkaya (Hatay, Elazıg, Turkey)
        N69.Changes in peripheral blood mononuclear cells subpopulation after RFA in patients with renal cell carcinoma, J. Michajłowski*, M. Matuszewski, I. Michajłowski, K. Ruckermann-Dziurdzińska, J.M. Witkowski, W. Biernat, K. Krajka (Gdańsk, Poland)
        N70.Systemic inflammatory reactions in patients after radiofrequency ablation of renal cell carcinoma, M. Matuszewski*, J. Michajłowski, I. Michajłowski, K. Krajka (Gdańsk, Poland)
        N71.The frequency of clinical symptoms in kidney cancer cases, R. Baltrimavicius*, A. Patasius, D. Milonas, M. Jievaltas (Kaunas, Lithuania)
        N72.Tumor size influence on cancer specific and overall survival after surgical renal carcinoma treatment, M. Milonas*, R. Baltrimavicius, A. Patasius, M. Jievaltas, S. Auskalnis (Kaunas, Lithuania)
        N73.Laparoscopic heminephrectomy in adult patients – initial experience, T. Borkowski*, J. Michalec, E. Bres (Warsaw, Poland)
        N74.Laparoscopic nephron sparing surgery: Early results of 38 cases, P. Slupski*, P. Jarzemski, S. Listopadzki (Bydgoszcz, Poland)
        N75.Should we broaden indications for treatment of T3c renal cell carcinoma with atrial thrombus?, S. Bąk*, Z. Dobrowolski, W. Lipczyński, B. Glazar, J. Sadowski (Cracow, Poland)
        Tabled 1
        17.00–17.30Debate: Androgen supplementation in aging males
        Chair: B. Darewicz, Bialystok (PL)
        Pro: P. Korrovits, Tartu (EE)
        Con: T. Drewa, Bydgoszcz (PL)
        17.30–18.00Lecture: Improving TUR-B with fluorescence cystoscopyPlenary room
        Sponsored by GE Healthcare

        Saturday, 12 September 2009

        Tabled 1
        08.00–09.20Prostate cancer–the burden of treatmentPlenary room
        08.00–08.20Active surveillance benefits and burden
        A. Rannikko, Helsinki (FI)
        08.20–08.40Voiding and storage dysfunction
        J. Nordling, Herlev (DK)
        08.40–09.00Management of ED
        A. Sikorski, Szczecin (PL)
        09.00–09.20Managing the burden of androgen deprivation
        M. Graefen, Hamburg (DE)
        09.20–09.50State-of-the-art lecture: What the urologist needs to know in female stress incontinence
        W. Artibani, Padua (IT)
        09.50–10.10Coffee break and poster viewing
        Tabled 1
        10.10–11.50Poster session 6: External genitalRoom 1
        N76.Results of an analgesia method in varicocelectomy under local anaesthesia for pain relief, A.B. Baseskioğlu* (Osmaniye, Turkey)
        N77.Risk-adapted management for patients with clinical stage I non-seminomatous germ cell tumor of testis, S. Güney, N. Güney, C. Sönmez*, E. Ergenekon (İstanbul, Turkey)
        N78.Endoscopic versus open hydrocelectomy for the treatment of adult hydroceles, L. Emir, M. Sunay*, Y. Karakaya, M. Dadalı, D. Erol (Ankara, Turkey)
        N79.Coenzyme Q10 treatment reduces lipid peroxidation, inducible and endothelial nitric oxide synthases and germ cell-specific apoptosis in testicular ischemia/reperfusion injury, B. Erol*, M. Bozlu, V. Hanci, H. Tokgoz, S. Bektas, G. Mungan (Zonguldak, Mersin, Turkey)
        N80.Fournier's gangrene: Overview of prognostic factors and definition of new prognostic parameter, B. Erol*, A. Tuncel, V. Hanci, H. Tokgoz, A. Abdulkadir, B. Akduman, E. Kargi (Zonguldak, Ankara, Turkey)
        N81.Long-term outcome after postchemotherapy retroperitoneal lymphadenectomy in patients with residual teratoma, D. Argirovic*, A. Argirovic, V. Stanic (Belgrade, Serbia)
        N82.Comparison of local anaesthetic effects of tramadol with prilocaine during circumcision procedure, E. Kargi, A. Isıkdemir, H. Tokgoz, B. Erol*, F. Isıkdemir, V. Hanci, C. Payasli (Zonguldak, Turkey)
        N83.High risk clinical stage A nonseminomatous testicular tumors: Primary retroperitoneal lymphadenectomy or cisplatin-based chemotherapy?, D. Argirovic*, A. Argirovic (Belgrade, Serbia)
        N84.Extremely low occurrence of late events following adjuvant carboplatin chemotherapy for clinical stage A seminomatous testicular tumors, D. Argirovic*, A. Argirovic (Belgrade, Serbia)
        N85.Surgical treatment of hypererectio, J.E. Baginska*, W. Piaskowski, K. Krajka (Gdańsk, Poland)
        N86.Hereditary behavior of varicocele, A. Gökçe*, M. Davarcı, F.R. Yalçınkaya, E.O. Güven, Y.S. Kaya, M.R. Helvacı, M.D. Balbay (Hatay, Turkey)
        N87.Relationship of varicocele with height and obesity in men presenting with infertility, A. Gökçe*, M. Davarcı, F.R. Yalçınkaya, E.O. Güven, M.D. Balbay (Hatay, Turkey)
        N88.Protective effect of vitamine E and melatonin against radiation induced damage in testis of rat, F.R. Yalçınkaya, A. Gökçe*, E.O. Güven, M. Davarcı, G. Cikim, H. Yekeler, M.D. Balbay (Hatay, Kahramanmaraş, Elazig, Turkey)
        N89.Usefulness of dermoscopy for differentiation of pearly penile papules and genital warts, I. Michajłowski*, J. Michajłowski, M. Sobjanek, A. Włodarkiewicz, M. Matuszewski, K. Krajka (Gdańsk, Poland)
        N90.The real-life safety and efficacy of vardenafil: an international post-marketing surveillance study – results from 2543 Polish patients, B. Darewicz, J. Kudelski*, M. Skrodzka, M. Chlabicz, E. Malczyk (Bialystok, Poland)
        N91.Peyronie's disease – surgical treatment outcomes, A. Zelvys*, B. Dainys, F. Jankevicius (Vilnius, Lithuania)
        N92.Sequential high-dose chemotherapy with hematopoietic stem-cell support in poor risk, relapsed or refractory germ-cell tumor patient treatment: Lithuanian experience, J. Korsakas*, K. Andrekute-Aleksiejiene, A. Bukauskas, B. Brasiuniene, I. Trociukas, F. Jankevicius, L. Griskevicius (Vilnius, Lithuania)
        N93.The value of radical radiotherapy in patients with penile cancer, W. Majewski, B. Bojanowski* (Gliwice, Poland)
        Tabled 1
        10.10–11.50Poster session 7: Stones and ReconstructionRoom 2
        N94.Impact of stone location on success rates of ureteroscopic pneumolithotripsy, C. Sönmez*, S. Arısan, S. Güney, O. Akca, A. Dalkılıc, E. Ergenekon (İstanbul, Turkey)
        N95.Heavy metals in stones and urine of stone formers, M. Słojewski*, B. Czerny, K. Safranow, A. Pawlik, M. Droździk, E. Byra, A. Gołąb, D. Chlubek, A. Sikorski (Szczecin, Poland)
        N96.Urethral pull-through operation for posterior urethral stricture: Outcomes of a 20-year experience, M. Sunay*, M. Dadalı, A. Karabulut, L. Emir, D. Erol (Ankara, Turkey)
        N97.Calcium phosphate stone morphology: plain radiographic findings and interobserver variabilities, H. Tokgoz, O. Turksoy, A. Yildiz, I. Unal, B. Erol*, S. Toparli, G. Mungan (Zonguldak, Adana, Urfa, Turkey)
        N98.Pain perception during shock wave lithotripsy (SWL): Does it correlate with patient and stone characteristics?, H. Tokgoz, V. Hanci, O. Turksoy, B. Erol*, B. Akduman, A. Mungan (Zonguldak, Turkey)
        N99.Comparison of the analgesic effects of dexketoprofen and diclofenac during shockwave lithotripsy: A randomized, double-blind clinical trial, H. Tokgoz, S. Yurtlu, V. Hanci, O. Turksoy, B. Erol*, B. Akduman, A. Mungan (Zonguldak, Turkey)
        N100.The alternative technique of ureterointestinal anastamosis with antireflux protection, I.G. Aghajanyan, A.A. Tsaturyan, Sh.B. Danielyan, O.E. Dilanyan* (Yerevan, Armenia; Moscow, Russia)
        N101.The analysis of the way of the treatment of staghorn stones in a kidney, J. Kawecki, W. Duda, H. Augustyniak, P. Chwastek* (Katowice, Poland)
        N102.Feasibility of prepuce reconstruction in hypospadias repair, M.K. Orkiszewski*, J.A. Madej (Poznań, Bydgoszcz, Poland)
        N103.Colics from the heart, M.S. Ahmad*, B.D.R. Gowda, D. Chadwick, G.P. Naisby (Stockton on Tees, Middlesbrough, United Kingdom)
        N104.Reimplantation of the strictured ureter – laparoscopic approach, A. Gołąb*, M. Słojewski, M. Soczawa, B. Gliniewicz, A. Sikorski (Szczecin, Poland)
        N105.Evaluation of renal function following extracorporeal shock wave lithotripsy (ESWL): The use of parametric clearance kidney scintigrams, T. Konecki*, I. Frieske, J. Kusmierek, M. Sosnowski (Lodz, Poland)
        N106.Nephrostomy in pregnancy, L. Wojnar*, A. Antczak, Z. Kwias (Poznań, Poland)
        N107.Hair stem cells for bladder regeneration in rats, preliminary results, T. Drewa*, R. Joachimiak, A. Kaznica, V. Sarafian, M. Pokrywczynska (Bydgoszcz, Poland; Plovdiv, Bulgaria)
        Tabled 1
        11.50–12.30Debate on chemoprevention of prostate cancerPlenary room
        Chair: M. Graefen, Hamburg (DE)
        Benefits: M. Marberger, Vienna (AT)
        Risks: W. Artibani, Padua (IT)
        12.30Awards and closing remarks
        A. Sikorski, Szczecin (PL)
        M. Marberger, Vienna (AT)